🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 88 of 116

  1. AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  2. AMG 509

    BEONE MEDICINES AUS PTY LTD

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  3. AMT-116

    Multitude Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  4. AMT-676

    Multitude Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  5. APL-1202 and APL-1501 (Single ascending dose)

    Jian Li

    Bladder Cancer

    phase 1 small molecule active

    1 trial

  6. APR-1051

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  7. APR-246

    Aprea Therapeutics

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  8. APTO-253

    Aptose Biosciences

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial

  9. APVO436

    Aptevo Therapeutics

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  10. APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

    Pyxis Oncology

    Glioblastoma Multiforme

    phase 1 mab active

    1 trial

  11. ARISE with AR

    BRIGHT MINDS BIOSCIENCES INC.

    Pediatric Cancer

    phase 1 other active

    1 trial

  12. ARO-HIF2

    Arrowhead Pharmaceuticals Ireland Limited

    Clear Cell Renal Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  13. ARQ 197

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  14. ASTX660

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  15. ATA3219

    Evidence Based Cataract Study Group

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  16. ATG-010 and ATG-008

    Shanghai Antengene Corporation Limited

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 1 other terminated

    1 trial

  17. ATI-2231

    Aclaris Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  18. ATRA

    United Therapeutics Europe Ltd

    Pancreatic Adenocarcinoma

    phase 1 small molecule completed

    1 trial

  19. AU-011

    Aura Biosciences

    Non-muscle-invasive Bladder Cancer

    phase 1 small molecule active

    1 trial

  20. AVE0005 (aflibercept)

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 1 small molecule completed

    1 trial

  21. AVI-4126 Injection (RESTEN-NG®)

    Sarepta Therapeutics

    Neoplasms

    phase 1 small molecule completed

    1 trial

  22. AVN-944 capsules for oral administration

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Leukemia

    phase 1 small molecule completed

    1 trial

  23. AZD0530

    AstraZeneca

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  24. AZD2014 3 on/4 off & weekly paclitaxel

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  25. AZD3514

    AstraZeneca

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  26. AZD5363+Olaparib+Durvalumab

    Hospital Authority, Hong Kong

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  27. AZD6244

    AstraZeneca

    Neoplasms,

    phase 1 small molecule completed

    1 trial

  28. AZD7762

    AstraZeneca

    Cancer

    phase 1 small molecule terminated

    1 trial

  29. AZD9150

    IONIS PHARMACEUTICALS INC

    Advanced Adult Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  30. Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

    Eli Lilly Co.

    Prostatic Neoplasms

    phase 1 other active

    1 trial

  31. AdV-tk

    Candel Therapeutics

    Pancreatic Adenocarcinoma

    phase 1 mab completed

    1 trial

  32. Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

    United Therapeutics Europe Ltd

    Urothelial Carcinoma

    phase 1 mab active

    1 trial

  33. Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

    CytoMed Therapeutics Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  34. Aflibercept (AVE0005)

    Regeneron UK Limited

    Neoplasm Malignant

    phase 1 small molecule completed

    2 trials

  35. Alisertib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  36. Alisertib

    Takeda

    B-cell Follicular Lymphoma

    phase 1 small molecule completed

    1 trial

  37. Alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    7 trials

  38. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  39. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial

  40. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam Therapeutics

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  41. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

    IDEAYA Biosciences

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  42. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  43. An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Solid tumors and ovarian cancer

    phase 1 other active

    1 trial

  44. An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  45. An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

    AstraZeneca AB

    Breast Cancer

    phase 1 other active

    1 trial

  46. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  47. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib Tablets 100 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with Bosulif (bosutinib) 100 mg, Manufactured and Packed by: Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee, Freiburg, Germany, Imported by: Pfizer Brasil Ltda. Rodovia Presidente Castelo Branco, nº32501, km 32.5 CEP 06696-000 – Itapevi – SP, in healthy adult, huma

    Lacuna Pharma Pty Ltd

    myeloid leukemia

    phase 1 other active

    1 trial

  48. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 160 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subject

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.